GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (BOM:532296) » Definitions » Revenue

Glenmark Pharmaceuticals (BOM:532296) Revenue : ₹132,090 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Revenue?

Glenmark Pharmaceuticals's revenue for the three months ended in Dec. 2023 was ₹24,603 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₹132,090 Mil. Glenmark Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2023 was ₹87.17. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹467.92.

Good Sign:

Glenmark Pharmaceuticals Ltd has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Glenmark Pharmaceuticals was 12.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 7.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Glenmark Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 50.10% per year. The lowest was 5.50% per year. And the median was 12.90% per year.


Glenmark Pharmaceuticals Revenue Historical Data

The historical data trend for Glenmark Pharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Revenue Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 97,050.84 103,972.28 108,060.26 121,741.98 127,254.33

Glenmark Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30,627.50 42,518.60 33,361.47 31,606.87 24,602.90

Competitive Comparison of Glenmark Pharmaceuticals's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Revenue falls into.



Glenmark Pharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹132,090 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glenmark Pharmaceuticals  (BOM:532296) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Glenmark Pharmaceuticals Revenue Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals (BOM:532296) Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (BOM:532296) Headlines

No Headlines